Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax files 2025 financial reports with French and U.S. regulators, reaffirming transparency and ongoing clinical developments

By Priya Menon ABVX

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

ABVX

Abivax SA, a clinical-stage biotechnology firm focused on immunology therapies, has filed its Universal Registration Document with the French AMF and its 20-F annual report with the U.S. SEC, covering its 2025 financial year. The filings include detailed financial results, corporate governance disclosures, and auditor reports. The company continues advancing its lead drug candidate obefazimod (ABX464) in Phase 3 trials for ulcerative colitis.

Key Points

Abivax filed comprehensive 2025 financial and governance reports with both French and U.S. regulatory agencies, demonstrating regulatory compliance and transparency.
The company is a clinical-stage biotech developing immunomodulatory therapies for chronic inflammatory diseases.
Its lead drug candidate, obefazimod (ABX464), is in late-stage Phase 3 clinical trials targeting moderately to severely active ulcerative colitis.
The filings may impact investor confidence in the biotechnology and pharmaceutical sectors, particularly in immunology-focused drug development.

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 23, 2026.

The Universal Registration Document includes the 2025 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.

The documents will be available for download on the website of Abivax (www.abivax.com/investors), the AMF (www.amf-france.org), and the SEC (www.sec.gov/edgar).

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Attachment

2026_04_01_Abivax Publishes Financial Reports with Regulatory Agencies

Risks

Clinical-stage status entails significant uncertainty as late-stage trials may fail or encounter delays, impacting the company’s financial outlook and valuation.
Dependence on successful development and regulatory approval of obefazimod introduces development and regulatory approval risks affecting company future revenues and market position.
Potential market risks include competition in the biotechnology sector, particularly in inflammatory disease therapeutics, that could affect Abivax's market share and growth prospects.

Menu

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Key Points

Risks

More from Press Releases